ANTHEM — Anthem BioSciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapHigh Flyer

Annual income statement for Anthem BioSciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	PROSPECTUS	PROSPECTUS	PROSPECTUS	PROSPECTUS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	11,032	12,313	10,569	14,194	18,446
Cost of Revenue
Gross Profit	6,220	7,860	6,786	7,877	10,525
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	7,577	7,238	6,299	9,957	12,626
Operating Profit	3,456	5,075	4,270	4,236	5,820
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,656	5,461	4,973	4,773	6,569
Provision for Income Taxes
Net Income After Taxes	2,713	4,055	3,852	3,673	4,513
Net Income Before Extraordinary Items
Net Income	2,713	4,055	3,852	3,673	4,513
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,713	4,055	3,852	3,673	4,513
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	4.83	7.22	6.01	6.55	8.04